The primary goal of the PPTC is to identify new agents that have the potential for significant activity when clinically evaluated against selected childhood cancers.
The Pediatric Preclinical Testing Consortium (PPTC) is a comprehensive program to systematically evaluate new agents against childhood solid tumor and leukemia models. The PPTC is supported through an NCI research contract to The Research Institutte at Nationwide Children’s Hospital with Dr. Peter Houghton as the Principal Investigator. Testing occurs both at The Research Institute and also at subcontract sites that have expertise in specific childhood cancers.
The consortium is based on a substantial body of data showing that appropriate childhood cancer preclinical in vivo models can recapitulate the anti-tumor activity of known effective agents and can prospectively identify novel agents subsequently shown to have clinical activity against specific cancers of children and adolescents. By facilitating development of a more reliable pediatric new agent prioritization process, the Pediatric Preclinical Testing Consortium will contribute to the goal of identifying more effective treatments for children with cancer.
PPTP Principal Investigators
- Dr. Peter Houghton, Ph.D.
Greehey Children’s Cancer Research Institute
- Dr. E. Anders Kolb, M.D.
A.I duPont Children’s Hospital, Wilmington
- Dr. Richard Gorlick, M.D.
Children’s Hospital at Montefiore, Albert Einstein College of Medicine
- Dr. Stephen Keir, Ph.D.
Preston Robert Tisch Brain Tumor Center, Duke University
- Dr. John Maris, M.D.
Children’s Hospital of Philadelphia
- Dr. Richard Lock, Ph.D.
Children’s Cancer Institute, Randwick, Australia
- Dr. C. Patrick Reynolds, M.D., Ph.D.
Texas Tech University Health Science Center, Lubbock